Sharemaestro Newsreel

United Therapeutics CEO Martine Rothblatt sells $4.96 million in stock

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares worth $4.96 million on July 29, 2026, after exercising stock options. The sale was executed under a pre-arranged 10b5-1 trading plan and occurred after an 86% return in the stock over the past …

Indivior Number of Employees 2026 | Employee Count & Headcount Data

Indivior Ltd. has an estimated 1,015 employees worldwide as of March 2026, marking a 25.4% decline in headcount since 2023. The Pharmaceuticals company, headquartered in Bon Air, Virginia, is actively hiring with 50 job postings in 2026, though this represents a 5.8% decline from …

Perrigo Announces Quarterly Dividend

DUBLIN, July 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash …

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has received an average "Hold" rating from six brokerages, with an average 12-month price target of $14.87. Recent analyst actions were mixed, including Goldman Sachs cutting its target to $14 (neutral) and Bank of America lowering its target …

HUTCHMED (China) 1H Rev $278.3M >HCM

This article reports that HUTCHMED (China) achieved a revenue of $278.3 million in the first half of the year. The company's stock symbol is HCM.

Takeda Pharmaceutical Q1 Earnings Call Highlights

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its mature portfolio. Revenue …

H.C. Wainwright reiterates Neutral stock rating on Alkermes

H.C. Wainwright reiterated a Neutral rating on Alkermes (NASDAQ:ALKS) shares following strong second-quarter results, where proprietary product sales rose 34% year-over-year, exceeding consensus estimates. Despite impressive sales for products like Vivitrol and the Aristada family, and significant growth in Lybalvi prescriptions and Lumryz sales, …

SIGA CEO and CFO Join Aug. 6 Business Update Webcast

SIGA Technologies, Inc. (Nasdaq: SIGA) announced that its CEO Diem Nguyen and CFO Daniel Luckshire will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 P.M. ET. The call will provide a business update following the release of the company's …

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

SIGA Technologies Inc. announced that it will host a webcast and conference call on August 6, 2026, at 4:30 P.M. ET to provide a business update following the release of its second-quarter 2026 financial results. The call will feature CEO Diem Nguyen and CFO …

Earnings call transcript: Takeda Q1 2026 results show steady growth, stock slips premarket

Takeda Pharmaceutical reported Q1 2026 results indicating steady growth, with revenue reaching JPY 1.22 trillion, a 10.2% increase at actual exchange rates, though declining 0.5% at constant currency. Despite core EPS falling due to prior-year tax benefits, the company maintained its full-year guidance and …

HUTCHMED Number of Employees 2026 | Employee Count & Headcount Data

HUTCHMED (China) Ltd. has a global workforce of 1,789 employees as of March 2026, marking a 1.2% decline since 2023. The company is actively hiring, with 5 job postings in 2026, though hiring velocity has slowed significantly. Its workforce is concentrated in China, and …

United Therapeutics (UTHR) CEO exercises 9,500 options, sells shares under plan

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share and subsequently sold these 9,500 shares on July 29, 2026, under a pre-arranged 10b5-1 trading plan. The shares were sold in multiple open-market transactions …

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Biofrontera Inc (BFRI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Biofrontera Inc (BFRI), stating its current valuation score is 9.06 and ranks 55 out of 155 in the Pharmaceuticals industry. It highlights the company's P/E ratio of -1.21 but notes that relevant data for P/B, P/S, and …

REG - Hutchmed China Ltd - HUTCHMED Reports 2026 Interim Results

HUTCHMED (China) Limited reported its 2026 interim financial results, highlighting a strong recovery in China product sales for ELUNATE® and SULANDA® with over 40% growth each, alongside a significant expansion of FRUZAQLA® sales ex-US. The company maintained profitability while increasing R&D investment, focusing on …

Journey Medical Corp (DERM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Journey Medical Corp (DERM), detailing its price momentum score, support and resistance levels, and indicator and moving average readings. As of August 3, 2026, DERM had a price momentum score of 4.06, with the stock trading between …

[6-K] Haleon plc Current Report (Foreign Issuer)

Haleon plc reported strong financial results for the first half of 2026, with revenue reaching £5,602m, an increase of 2.2% on a reported basis and 2.6% organically. The company saw adjusted diluted EPS rise by 12.0% to 10.3p and adjusted operating profit increase by …

Evolus Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Evolus, Inc. (EOLS), a performance beauty company specializing in cash-pay aesthetic medical products. It outlines the company's key products, Jeuveau and Evolysse, and includes essential corporate information such as its CEO, IPO date, employee count, and contact …

RBF Capital LLC Takes Position in Perrigo Company plc $PRGO

RBF Capital LLC has acquired a new position in Perrigo Company plc (NYSE:PRGO), purchasing 180,000 shares valued at approximately $1.93 million. This acquisition makes RBF Capital LLC the owner of 0.13% of Perrigo's stock, contributing to the 95.91% institutional ownership of the company. Perrigo …

SNOA|Sonoma Pharmaceuticals Inc|Price:1.100|Chg%:-0.040

Sonoma Pharmaceuticals Inc. (SNOA) shows strong fundamentals with high growth potential, averaging 53.35% revenue growth over three years. Despite recent stock market underperformance, its valuation is considered fairly valued within the Pharmaceuticals industry. The company, which develops and produces stabilized hypochlorous acid (HOCl) products …

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9% Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 9.9% year on year to $796.2 million. The company's full-year revenue guidance of $3.15 billion …

Is Eton Pharmaceuticals (ETON) Quietly Reframing Its Orphan-Drug Strategy With KHINDIVI’s Label Expansion Bid?

Eton Pharmaceuticals (ETON) has filed to expand the label for its hydrocortisone oral solution, KHINDIVI, to include younger pediatric patients with adrenocortical insufficiency. This move aims to broaden treatment options for a rare disease population, potentially impacting Eton's orphan-therapy investment narrative and future revenue …

SCYNEXIS Inc (SCYX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for SCYNEXIS Inc (SCYX), ranking it 104 out of 155 in the Pharmaceuticals industry with a score of 3.19. Key metrics such as beta, VaR, maximum drawdown, volatility, and Sharpe Ratio are presented to detail the stock's performance …

Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC reduced its stake in Dr. Reddy's Laboratories (NYSE:RDY) by 9.3% in the first quarter, selling 108,731 shares. Despite this, several other institutional investors increased their holdings in the company. Analyst ratings for Dr. Reddy's Laboratories are predominantly "Reduce," with the …

PBH|Prestige Consumer Healthcare Inc|Price:52.180|Chg%:+0.460

Prestige Consumer Healthcare Inc. (PBH) shows healthy fundamentals and high growth potential, with its valuation considered fairly priced within the Pharmaceuticals industry. Institutional ownership is notably high, and analysts have consistently rated the stock as "Buy," with a target price of $66.00. Despite strong …

Amneal: Q2 Earnings Snapshot

181,294 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund has acquired a new stake of 181,294 shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), valued at approximately $5.46 million. This purchase is part of broader institutional investment activity, with several other hedge funds also increasing their holdings …

Takeda Pharmaceutical (NYSE: TAK) Q1 2026 revenue ¥1.22T, EPS ¥71.65

Takeda Pharmaceutical Company Limited reported consolidated IFRS results for Q1 2026, with revenue reaching ¥1.22 trillion, a 10.2% year-on-year increase primarily due to Japanese yen depreciation. Despite increased revenue and operating profit, net profit attributable to owners declined by 8.9% to ¥113.2 billion, resulting …

Cronos Group Inc (CRON) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Cronos Group Inc (CRON) by TradingKey, noting its current valuation score of 8.55, ranking 54 out of 155 in the Pharmaceuticals industry. It highlights the company's current P/E ratio of -646.12, which is significantly below its recent …

Earnings call transcript: Haleon posts stronger H1 2026 growth, shares dip

Haleon reported stronger first-half sales growth in Q2 2026, driven by improved performance in oral care, pain relief, and emerging markets, and maintained its full-year outlook. Despite the positive operational update, shares dipped by 0.78% in premarket trading. The company highlighted efficiency gains and …

Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?

Viatris (VTRS) is expected to report flat earnings for Q2 2026 compared to the previous year, but with a 2.8% increase in revenues to $3.68 billion. The Zacks Earnings ESP indicates a potential negative surprise for Viatris, as the Most Accurate Estimate is lower …

Eton Pharmaceuticals (ETON) Projected to Announce Quarterly Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to announce its Q2 2026 earnings on Thursday, August 6th, with analysts projecting earnings of $0.13 per share and revenue of $27.1130 million. The company reported a miss in its previous quarter with $0.05 EPS against an estimated $0.10. …

EVO|Evotec SE|Price:1.930|Chg%:-0.030

This article provides a comprehensive stock analysis of Evotec SE (EVO) by TradingKey. It highlights that Evotec SE has healthy fundamentals, high growth potential, and is considered fairly valued within the Biotechnology & Medical Research industry. The analysis also covers key insights such as …

Canadian Stock Movers for Thursday | Bausch Health Companies Inc Was the Top Gainer; Capital Markets Led Gains

Bausch Health Companies Inc. (BHC.TO) was Thursday's top gainer in Canadian stock markets, rising 12.18% to close at C$7.32. The Capital Markets sector broadly led Thursday's gains, increasing by 2.22%. Trading volume was robust, with 364.57 million shares changing hands, exceeding the 10-day average.

Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There?

Teva Pharmaceutical Industries (TEVA) recently raised its 2026 revenue guidance despite reporting a quarterly net loss and asset impairment charges, leading to share price fluctuations. Simply Wall St's analysis suggests the stock is 15.1% undervalued with an implied fair value of $40.90, driven by …

Biotech Stocks At 52-Week Highs - ANIK & CHE Rise With Q2 Results, ICUI, NBIX, RPRX

Several biotech stocks, including Anika Therapeutics (ANIK), Chemed Corporation (CHE), ICU Medical (ICUI), Neurocrine Biosciences (NBIX), and Royalty Pharma (RPRX), reached new 52-week highs on July 29, 2026. This surge was primarily driven by strong second-quarter financial results and ongoing positive clinical research updates …